HighGravityDataEli Lilly — Oct 30, 2025 release
Fiscal 2025 third-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000059478-25-000251
Showing in the filing
EPS (non-GAAP)
“$23.00 to $23.70”
Period
FY2025
Measure
Company-defined measure
Source
Prose
All guidance in this release · 12
Revenue for FY2025
“$63.0 billion to $63.5 billion”
EPS (non-GAAP) for FY2025
“$23.00 to $23.70”
Performance margin, reported basis for FY2025
“43.5% and 44.5%”
Performance margin, non-GAAP basis for FY2025
“45.0% and 46.0%”
Other income (expense), non-GAAP basis for FY2025
“$700 million to $600 million”
Estimated effective tax rate (reported) for FY2025
“approximately 19%”
Earnings per share (reported) for FY2025
“$21.80 to $22.50”
EPS (reported) for FY2025
“$21.80 to $22.50”
Earnings per share (non-GAAP) for FY2025
“$23.00 to $23.70”
Other Income/(Expense) (non-GAAP) for FY2025
“Unchanged”
Tax Rate (non-GAAP) for FY2025
“Unchanged”
Tax Rate (reported) for FY2025
“Unchanged”
Exhibit 99.1 · the passage around this item
… earlier in the release
• Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion; reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised to be in the range of $23.00 to $23.70. • Pipeline progress included positive results in four Phase 3 trials of orforglipron, across type 2 diabetes and obesity, with plans to submit to global regulatory authorities by the end of the year for the treatment of obesity. • Regulatory progress included U.S. FDA approval of Inluriyo (imlunestrant) for certain adults with advanced or metastatic breast cancer. • Manufacturing progress included announcements of two new facilities in Virginia and Texas, and the expansion of Lilly's existing Puerto Rico site. INDIANAPOLIS, October 30, 2025 - Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third-quarter of 2025. “Lilly delivered another strong quarter, with 54% revenue growth year-over-year driven by continued demand for our incretin portfolio,” said David A. Ricks, Lilly chair and CEO. “We advanced orforglipron through four additional Phase 3 trials, enabling global obesity submissions by year-end, and we achieved U.S. FDA approval of Inluriyo (imlunestrant)—marking key progress across our pipeline. We continue to increase manufacturing capacity, announcing new facilities in Virginia and Texas and an expansion of our site in Puerto Rico.” Eli Lill
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.